Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) saw unusually-high trading volume on Tuesday . Approximately 2,385,252 shares were traded during trading, a decline of 61% from the previous session’s volume of 6,092,242 shares.The stock last traded at $2.73 and had previously closed at $2.62. Analyst Ratings Changes ESPR has been the subject […]
Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) saw unusually-strong trading volume on Tuesday . Approximately 2,385,252 shares were traded during mid-day trading, a decline of 61% from the previous session’s volume of 6,092,242 shares.The stock last traded at $2.73 and had previously closed at $2.62. Wall Street Analyst Weigh In ESPR has […]
Friday, the FDA approved broad new label expansions for Esperion Therapeutics Inc’s ESPR NEXLETOL (bempedoic acid) Tablets and NEXLIZET (bempedoic acid and…
Latest FDA-approved label expansions for Esperion Therapeutics' NEXLETOL (bempedoic acid) Tablets and NEXLIZET (bempedoic acid and ezetimibe) Tablets for broadened indications for cardiovascular risk reduction and LDL-C lowering.
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) saw unusually large options trading activity on Monday. Investors purchased 11,472 call options on the stock. This is an increase of approximately 223% compared to the typical daily volume of 3,554 call options. Analyst Ratings Changes Several brokerages have recently issued reports on ESPR. Bank of America […]